McKesson’s Strong Quarter Highlights Shift Toward Post Separation Focus
McKesson (NYSE:MCK) reported strong fiscal third-quarter results, driven by momentum in oncology, biopharma services, and pharmaceutical distribution. The company is progressing with the planned IPO of its medical surgical business by the second half of 2027, which will enable McKesson to focus on its core drug distribution and services. This strategic shift and solid financial performance, including raised full-year EPS guidance, reflect the company's evolving business model and potential for future growth in specialty pharmaceuticals.
https://simplywall.st/stocks/us/healthcare/nyse-mck/mckesson/news/mckessons-strong-quarter-highlights-shift-toward-post-separa